JNJ's Phase 2 Study Of Nipocalimab Shows Improvement In Disease Activity In Sjögren's Disease
(RTTNews) - Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's ...
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Donald Trump Supporters Are Already Finding Out What Their Vote Actually Meant, And The Stories Are Going Viral
"Latino male Trump voter told CNN mass deportation won't extend to law-abiding workers. 'That wouldn’t be fair. They need to ...
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Renaissance Tech adds Micron, exits Broadcom, among Q3 trades
Renaissance Technologies took new stakes in Micron Technology (NASDAQ:MU), Eli Lilly (NYSE:LLY), and Cisco Systems ...
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction ...
Business Insider16h
Johnson & Johnson announces results from analyses of Phase 2 DAHLIAS study
Try Now>> See today’s best-performing stocks on TipRanks >> Read More on JNJ: Johnson & Johnson NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Tuscaloosa Get Up 3 to feature star-studded musical lineup
Get-Up 3 will feature Brittany Howard of Alabama Shakes, Mike Cooley of Drive-by Truckers, Lee Bains and more.
After a break from acquisitions, Avantor is getting ready to break out its M&A playbook again
Historically an active player in the M&A space, Radnor-based Avantor has not found itself so busy in that realm during the ...
Vaccines makers close lower on reports RFK Jr may head HHS
Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower
Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape ...
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.